News from Cassava Sciences, Moderna and Sorrento Therapeutics 
Cassava Sciences 
Cassava Sciences (SAVA) announced that clinical results of its Phase 2b study of sumifilam have been selected as a late-breaking oral presentation by the 13th international conference on Clinical Trials on Alzheimer’s Disease (CTAD).
What is CTAD?
CTAD is a prestigious annual conference focused on Alzheimer’s . . .